Daniel L. Flynn's most recent trade in Deciphera Pharmaceuticals Inc was a trade of 1,655 Common Stock done at an average price of $14.4 . Disclosure was reported to the exchange on June 16, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.40 per share. | 16 Jun 2023 | 1,655 | 57,158 (0%) | 0% | 14.4 | 23,835 | Common Stock |
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 65,900 | 65,900 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 16,488 | 60,183 (0%) | 0% | 0 | Common Stock | |
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.10 per share. | 15 Feb 2023 | 1,370 | 58,813 (0%) | 0% | 15.1 | 20,686 | Common Stock |
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.24 per share. | 17 Jan 2023 | 2,403 | 43,695 (0%) | 0% | 21.2 | 51,043 | Common Stock |
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.75 per share. | 16 Jun 2022 | 1,768 | 46,098 (0%) | 0% | 10.8 | 19,006 | Common Stock |
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.05 per share. | 16 Feb 2022 | 1,366 | 47,866 (0%) | 0% | 9.0 | 12,362 | Common Stock |
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 82,000 | 82,000 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 20,500 | 49,232 (0%) | 0% | 0 | Common Stock | |
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 49,900 | 49,900 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 11,100 | 17,632 (0%) | 0% | 0 | Common Stock | |
| Deciphera Pharmaceuticals Inc | Daniel L. Flynn | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 48.87 per share. | 16 Feb 2021 | 508 | 6,532 (0%) | 0% | 48.9 | 24,826 | Common Stock |